From The Editor | January 1, 2024

A New Year At Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Ben Comer_450x300

Happy New Year to all of the business leaders, small and large biopharmaceutical companies, CDMOs and other service providers, scientists and academics, investors and technologists, public relations professionals and the patient advocates and physicians working to improve lives and health all over the globe. We appreciate the work you do, and we especially appreciate it when you take the time to converse with us about it, in detail, so we can pass your lessons forward.

More and more, those conversations are happening outside of the traditional office, a transition catalyzed by the COVID-19 pandemic. And while some companies are bringing workers back in person full-time, many others are offering their employees the flexibility to get the job done wherever there is coffee, internet access, and the drive to succeed. As a result, our monthly edition of Life Science Leader magazine, which has been published in print for over a decade, doesn’t reach as many readers in the small offices of start-up biotechs, or the large corporate offices of Big Pharma, as it once did.

Like the former biopharmaceutical office workers now creating their own workspaces outside of the office – and turning commute time into productive work time – Life Science Leader is following its readers in 2024 and published its last print magazine in December 2023. The decision was ultimately an easy one: Life Science Leader as a digital first publication better allows readers, wherever they are, to engage with the information and individuals appearing in our articles and digital media channels. More importantly, it helps readers explore their own specific areas of interest throughout Life Science Leader’s ever-growing collection of articles, digital events, expert contributed content, as well as specific industry information across the Life Science Connect network of publications, which includes Clinical Leader, Bioprocess Online, Cell & Gene, Outsourced Pharma, as well as new publications including Advancing RNA, Clinical Supply Leader, Clinical Tech Leader, and Drug Delivery Leader.

In some ways, Life Science Leader won’t change: we will still publish profiles of the leading movers and shakers bringing change to the biopharmaceutical industry, dissect new business and funding models, provide context and insight on policy and regulatory developments, examine waxing and waning therapeutic areas and development activities, and offer guidance from top industry executives on the leadership skills needed to succeed during a time of enormous scientific innovation and global instability.

In addition to the Life Science Leader content our readers have come to recognize over the last decade, we also will introduce new story types and angles across different media channels in 2024, offering readers more ways to connect and conduct business. To our current readers: thank you for reading, and please get in touch with any feedback you would like to offer on our editorial coverage: you can reach me at To our new readers (and viewers): we are thrilled to have you and welcome your thoughts as well.

If you will be in San Francisco for J.P. Morgan next week, get in touch! And best wishes for a fruitful, exciting, and healthy 2024.